[1] | Savage DG and Antman KH., 2002, Imatinib mesylate - a new oral targeted therapy, N Engl J Med., 346(9), 683-693. |
[2] | Croom KF and Perry CM., 2003, Imatinib mesylate: in the treatment of gastrointestinal stromal tumours, Drugs, 63(5), 513-522. |
[3] | Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D and Pazdur R., 2002, Approval summary: Imatinib mesylate in the treatmen od metastatic and/or unresectable malignant gastrointestinal stromal tumors, Clin Cancer Res., 8(10), 3034-3038. |
[4] | Hung KD, Van QL, Hoang GN and Bich PNT., 2019, Imatinib mesylate for patients with unresectable or reccurent gastrointestinal stromal tumors: 10-year experiance from Vietnam, Cancer Control, 26(1). |
[5] | https://doi.org/10.1177/1073274819863776. |
[6] | Goldman JM and Melo JV., 2003, Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N Engl J Med., 349(15), 1451-1464. |
[7] | Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J and Hehlmann R., 2009, Chronic Myeloid leukemia: An Update of Concepts and managment Recommendaions of European Leukemia Net, J Clin Oncol., 27(35), 6041-6051. |
[8] | Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S and Distler O., 2007, Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis, Arthritis Rheum., 56(1), 311-322. |
[9] | Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL., 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med., 344(14), 1031-1037. |
[10] | Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN, Gadner H, Sufliarska S, Stary J, Gschaidmeier H, Guilhot F and Suttorp M., 2006, Imatinib mesylate is effective in children with chronic myeloegenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation, Leukemia, 20(2), 187-192. |
[11] | Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ and Borden EC., 2008, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointenstinal stromal tumors expressing the kit receptor tyrosine kinase: S0033, J Clin Oncol., 26(4), 626-632. |
[12] | Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P and Perol D., 2007, Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption verusus continuation of treatment beyond 1 year: the French Sarcoma Group, J Clin Oncol., 25(9), 1107-1113. |
[13] | Demetri GD, von Mahren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al., 2002, Efficacy and safety of imatinib mesylate in advanced gastrointenstinal stromal tumors. N Engl J Med., 347(7), 472-480. |
[14] | Sawyers CL., 1999, Chronic Myeloid Leukemia. N Engl J Med., 340(17), 1330-1340. |
[15] | Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al., 2002, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med., 346(9), 645-652. |
[16] | Tamascar I and Ramanarayanan J., 2009, Targeted treatment of chronic myeloid leukemia: role of imatinib, Onco Targets Ther., 2, 63-71. |
[17] | Din OS and Woll PJ., 2008, Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate, Ther Clin Risk Manag., 4(1), 149-162. |
[18] | Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al., 2009, Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial, Lancet., 373, 1097-1104. |
[19] | Weisberg E and Griffin JD., 2001, Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients, Drug Resist Updat., 4(1), 22-28. |
[20] | Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R and Scapozza L., 2003, Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias, Lancet Oncol., 4(2), 75-85. |
[21] | Shah NP and Sawyers CL., 2003, Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias, Oncogene, 22(47), 7389-7395. |
[22] | Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM and Melo JV., 2003, MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models, Blood, 101(6), 2368-2373. |
[23] | Widmer N, Colombo S, Buclin T and Decosterd LA., 2003, Functional consequence of MDR1 expression on imatinib intracellular concentrations, Blood, 102(3), 1142. |
[24] | Cortes J, Talpaz M, Giles F, et al., 2002, High dose imatinib mesylate (STI571, gleevec) in patiens with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN), Proc ASCO., 21, 262A. |
[25] | Kantarjian H, Cortes J, O'Brien S, et al., 2002, High rates of early mayor and complete cytogenetic respones with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), Proc ASCO, 21, 261A. |
[26] | Lyseng-Williamson K and Jarvis B., 2001, Imatinib, Drugs, 61(12), 1765-1774. |
[27] | Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB and Force T., 2006, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nat Med., 12(8), 908-916. |
[28] | Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, Cambiaghi N, Pogliani E, Corneo G and Gnessi L., 2003, Gynaecomastia in men with chronic myeloid leukaemia after imatinib, Lancet., 361, 1954-1956. |
[29] | Deininger M, Buchdunger E and Druker BJ., 2005, The development of imatinib as a therapeutic agent for chronic myeloid leukemia, Blood, 105(7), 2640-2653. |
[30] | Cipurković A, Horozić E, Ljubijankić N, Odobašić A, Galijašević S and Saletović M., 2017, Synthesis and spectral characterization of Fe(II) and Mn(II) complexes with oral fluorouracil pro-drug Capecitabine, RASAYAN J Chem., 10(4), 1381-1390. |
[31] | Horozić E, Cipurković A, Ademović Z, Bjelošević D, Zukić A, Kolarević L, Husejnagić D and Hodžić S., 2018, Synthesis, spectral characterization and antimicrobial activity ofsome M(II) complexes with Ciprofloxacin, J.eng. process. manag., 10(2), 16-22. |
[32] | Haleblian J and McCrone W., 1969, Pharmaceutical applications of polymorphism, J Pharm Sci., 58(8), 911-929. |
[33] | Benvenuti S, Pellati F, Melegari M and Bertelli D., 2004, Polyphenols, Anthocyanins, Ascorbic Acid, and Radical Scavenging Activity of Rubus, Ribes, and Aronia, J Food Sci., 69(3), 164-169. |
[34] | Jiménez-Aspee F, Quispe C, Soriano CMP., Fuentes Gonzalez J, Hüneke E, Theoduloz C. and Schmeda-Hirschmann G., 2014, Antioxidant activity and characterization of constituents in copao fruits (Eulychnia acida Phil., Cactaceae) by HPLC–DAD–MS/MSn, Food Research Int., 62, 286-298. |
[35] | Veverka M, Simon P, Lokaj J and Veverková E., 2012, Crystal habit modifications of imatinib mesylate under various precipitation conditions, Monatsh Chem., 143(1), 65-71. |
[36] | Cipurković A, Horozić E, Crnkić A, Marić S, Ljubijankić N, 2016, Spectroscopic Investigations of Co(II) and Cu(II) Interaction with Imatinib Mesylate and Capecitabine. Bull Chem Tech B&H, 47, 11-16. |
[37] | Kumar Raja J., Sundar V. D., Magesh A. R., Nandha Kumar S., Dhanaraju M. D. 2010, Validated spectrophotometric estimation of Imatinib mesylate in pure and tablet dosage form. Int J Pharm & Tech, 2 (3), 490-495. |
[38] | Patil Smita J., Doijad Rajendra C., Dhumal Priya P. 2013, Development of UV-spectrophotometric method for the determination of Imatinib mesylate (ITM) in bulk and formulation. Asian J Pharm Clin Res, 6 (3), 54-57. |